These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31258036)

  • 41. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
    Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
    J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
    Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
    Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
    Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
    Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report.
    Goodman DJ; Milliken CU; Theiler RN; Nordstrom BR; Akerman SC
    J Dual Diagn; 2015; 11(3-4):248-57. PubMed ID: 26457976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
    Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
    Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and evaluation of a community-based buprenorphine treatment intervention.
    Fox AD; Sohler NL; Frost T; Lopez C; Cunningham CO
    Harm Reduct J; 2017 May; 14(1):23. PubMed ID: 28499432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting.
    O'Gurek DT; Jatres J; Gibbs J; Latham I; Udegbe B; Reeves K
    J Subst Abuse Treat; 2021 Aug; 127():108342. PubMed ID: 34134882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
    Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
    Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opiate overdose and health treatment options for opiate users in New South Wales, 1999-2002.
    Cook S; Indig D; Gray J; McGrath D
    N S W Public Health Bull; 2004; 15(7-8):125-31. PubMed ID: 15586207
    [No Abstract]   [Full Text] [Related]  

  • 51. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining Low-threshold Buprenorphine Treatment.
    Jakubowski A; Fox A
    J Addict Med; 2020; 14(2):95-98. PubMed ID: 31567596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study of a distress tolerance treatment for opiate-dependent patients initiating buprenorphine: rationale, methodology, and outcomes.
    Brown RA; Bloom EL; Hecht J; Moitra E; Herman DS; Stein MD
    Behav Modif; 2014 Sep; 38(5):730-59. PubMed ID: 24973401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Staring down the opioid epidemic.
    Unger JR
    J Fam Pract; 2017 Jan; 66(1):8. PubMed ID: 28188310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program.
    Kaucher KA; Caruso EH; Sungar G; Gawenus L; Hurlbut K; Sanchez DC; Broderick K
    Am J Emerg Med; 2020 Feb; 38(2):300-304. PubMed ID: 31387811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.
    Mittal L; Suzuki J
    Subst Abus; 2017; 38(3):261-264. PubMed ID: 26672650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preliminary results of the evaluation of the California Hub and Spoke Program.
    Darfler K; Sandoval J; Pearce Antonini V; Urada D
    J Subst Abuse Treat; 2020 Jan; 108():26-32. PubMed ID: 31400985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 59. Trends in Buprenorphine Treatment in the United States, 2009-2018.
    Olfson M; Zhang VS; Schoenbaum M; King M
    JAMA; 2020 Jan; 323(3):276-277. PubMed ID: 31961408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.